Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

2.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Review.

PMID:
24636263
3.

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Gadgeel SM, Wozniak A.

Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Review.

PMID:
23332287
4.

Epithelial Mesenchymal Transition in Aggressive Lung Cancers.

Mittal V.

Adv Exp Med Biol. 2016;890:37-56. doi: 10.1007/978-3-319-24932-2_3. Review.

PMID:
26703798
5.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
6.

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.

Ahsan A.

Adv Exp Med Biol. 2016;893:137-153. doi: 10.1007/978-3-319-24223-1_7. Review.

PMID:
26667342
7.

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.

van der Wekken AJ, Saber A, Hiltermann TJ, Kok K, van den Berg A, Groen HJ.

Crit Rev Oncol Hematol. 2016 Apr;100:107-16. doi: 10.1016/j.critrevonc.2016.01.024. Epub 2016 Jan 25. Review.

8.
9.

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.

Cadranel J, Ruppert AM, Beau-Faller M, Wislez M.

Crit Rev Oncol Hematol. 2013 Dec;88(3):477-93. doi: 10.1016/j.critrevonc.2013.06.009. Epub 2013 Jul 31. Review.

PMID:
23911281
10.

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.

Scaltriti M, Elkabets M, Baselga J.

Clin Cancer Res. 2016 Mar 15;22(6):1313-7. doi: 10.1158/1078-0432.CCR-15-1458. Epub 2016 Jan 13. Review.

11.

Chemotherapeutics-resistance "arms" race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer.

Singh PK, Silakari O.

Life Sci. 2017 Oct 1;186:25-32. doi: 10.1016/j.lfs.2017.08.001. Epub 2017 Aug 4. Review.

PMID:
28782530
12.

AXL-Driven EMT State as a Targetable Conduit in Cancer.

Antony J, Huang RY.

Cancer Res. 2017 Jul 15;77(14):3725-3732. doi: 10.1158/0008-5472.CAN-17-0392. Epub 2017 Jun 30. Review.

PMID:
28667075
13.

AXL kinase as a novel target for cancer therapy.

Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B.

Oncotarget. 2014 Oct 30;5(20):9546-63. Review.

14.

The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Jakobsen KR, Demuth C, Sorensen BS, Nielsen AL.

Transl Lung Cancer Res. 2016 Apr;5(2):172-82. doi: 10.21037/tlcr.2016.04.07. Review.

15.

Giving AXL the axe: targeting AXL in human malignancy.

Gay CM, Balaji K, Byers LA.

Br J Cancer. 2017 Feb 14;116(4):415-423. doi: 10.1038/bjc.2016.428. Epub 2017 Jan 10. Review.

16.

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.

Schoumacher M, Burbridge M.

Curr Oncol Rep. 2017 Mar;19(3):19. doi: 10.1007/s11912-017-0579-4. Review.

17.

Axl inhibitors as novel cancer therapeutic agents.

Shen Y, Chen X, He J, Liao D, Zu X.

Life Sci. 2018 Apr 1;198:99-111. doi: 10.1016/j.lfs.2018.02.033. Epub 2018 Feb 27. Review.

PMID:
29496493
18.

Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer.

Chen Y, Lu L, Feng B, Han S, Cui S, Chu X, Chen L, Wang R.

Oncotarget. 2017 May 30;8(22):36787-36799. doi: 10.18632/oncotarget.16375. Review.

19.

The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.

Zang H, Wang W, Fan S.

Cancer Chemother Pharmacol. 2017 Feb;79(2):227-231. doi: 10.1007/s00280-016-3130-7. Epub 2016 Aug 11. Review.

PMID:
27515517
20.

Targeted therapies in development for non-small cell lung cancer.

Reungwetwattana T, Dy GK.

J Carcinog. 2013 Dec 31;12:22. doi: 10.4103/1477-3163.123972. eCollection 2013. Review.

Supplemental Content

Support Center